Drugs / FURESTEM-RA Inj
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02221258 | Oct 2014 → Oct 2015 | rheumatoid arthritis | Kang Stem Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03618784 | Jul 2018 → Oct 2021 | rheumatoid arthritis | Kang Stem Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FURESTEM-RA Inj. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02221258 ↗ |
| Modality | Cell therapy | “FURESTEM-RA Inj. has huge possibility as cell therapy products for RA patients.” NCT02221258 ↗ |
| Route | Intravenous | “Administer the constituted cell suspension by IV infusion to a subject.” NCT03618784 ↗ |